Education
About Us
Working with TipRanks
Follow Us
Exicure (DE:2H0)
NASDAQ:2H0
2H0 Stock Chart & Stats
€4.08
€0.00(0.00%)
At close: 4:00 PM EST
€4.08
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€1.48 - €8.25
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€21.96M
Enterprise Value€21.57M
Total Cash (Recent Filing)€4.44M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-1.27
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding6,373,869
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)12.31
Price to Sales (P/S)166.76
P/FCF Ratio-28.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Differentiated Clinical Profile (burixafor)Burixafor’s rapid, same-day CD34+ mobilization and ~90% Phase 2 primary endpoint success create a durable clinical differentiation vs existing CXCR4 inhibitors that require overnight dosing. This structural advantage can lower logistics and cost barriers, aiding adoption in transplant settings and supporting expansion to new indications and registrational strategies.
Meaningfully Improved Balance Sheet LeverageThe reduction in debt and near-doubling of equity materially improved debt/equity from ~2.2x to ~0.88x, strengthening solvency and financial flexibility. This durable improvement lowers refinancing pressure and gives management more optionality to fund clinical programs or seek partnerships without immediate liquidity stress.
Strengthened Internal R&D And Integration Of GPCR AssetsBringing GPCR assets in-house and hiring senior drug development leaders with proven regulatory and translational track records builds durable internal capability. This raises the likelihood of efficient Phase 3 planning, regulatory interactions, and potential indication expansion, reducing dependence on external partners for core development functions.
Bears Say
Minimal Revenue And Persistent Operating LossesThe company remains a clinical-stage operation with negligible commercial revenue and sustained multi-year losses, limiting self-funding capacity. Persistently negative margins reduce financial resilience, increase dilution risk from future financings, and constrain long-term investment unless clinical programs translate to clear commercial prospects.
Ongoing Negative Operating Cash Flow And Funding RelianceAlthough burn has moderated, the company still consumes cash from operations and has historically volatile outflows. Continued negative OCF means structural reliance on external financing or asset monetization; this limits strategic freedom, can dilute shareholders, and makes multi-site pivotal trials harder to support without partners.
Program Concentration And Contractual ObligationsExicure’s value and near-term prospects are concentrated in burixafor. The $1M milestone payment and adjusted sublicensing economics create recurring cash obligations and reduce upside from future deals. This concentration means clinical setbacks, regulatory delays, or commercialization issues with burixafor would have outsized negative impacts on the company’s financial trajectory.
Exicure News
2H0 FAQ
What was Exicure’s price range in the past 12 months?
Exicure lowest stock price was €1.48 and its highest was €8.25 in the past 12 months.
What is Exicure’s market cap?
Exicure’s market cap is €21.96M.
When is Exicure’s upcoming earnings report date?
Exicure’s upcoming earnings report date is May 20, 2026 which is in 92 days.
How were Exicure’s earnings last quarter?
Exicure released its earnings results on Nov 07, 2025. The company reported -€0.326 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.326.
Is Exicure overvalued?
According to Wall Street analysts Exicure’s price is currently Overvalued.
Does Exicure pay dividends?
Exicure does not currently pay dividends.
What is Exicure’s EPS estimate?
Exicure’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Exicure have?
Exicure has 6,373,869 shares outstanding.
What happened to Exicure’s price movement after its last earnings report?
Exicure reported an EPS of -€0.326 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.263%.
Which hedge fund is a major shareholder of Exicure?
Currently, no hedge funds are holding shares in DE:2H0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Exicure
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Technical Analysis
Options Prices
Currently, No data available
---